Skip to main content
STLN logo

STLN · Starling Oncology, Inc. · Executive Compensation

Track STLN — free
$3.26 +0.06 (+1.88%) Play latest call Q2 2026 earnings call transcript
Market Cap
$326.37M
Shares
101.99M
Volume · Nov 18 4.68M Avg daily vol (3M) 2.45M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Daniel Virnich $1,934,930
Yale Podnos $775,905
Robert Carter $734,130
Fiscal 2024
Executive Total
Daniel Virnich $1,118,358
Mihir Shah $733,144
Jeremy Castle $622,220
Yale Podnos $610,332
Robert Carter $434,404
Fiscal 2023
Executive Total
Brad Hively $1,215,190
Daniel Virnich $808,129
Mihir Shah $801,743
Yale Podnos $591,284
Jeremy Castle $486,126
Fiscal 2022
Executive Total
Brad Hively $6,629,723
Daniel Virnich $3,244,461
Mihir Shah $2,264,237
Yale Podnos $1,249,186
Fiscal 2021
Executive Total
Brad Hively $11,635,536
Daniel Virnich $7,638,167
Scott Dalgleish $4,758,691
Fiscal 2020
Executive Total
Brad Hively $611,400
Daniel Virnich $418,684
Scott Dalgleish $317,583

Executive changes

Person Change Filed
Kimberly Tzoumakas Appointed 2026-02-23
Mark D. Stolper Appointed 2026-01-07
Gabriel Ling
“Mr. Ling’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-12-01
Anne McGeorge Appointed 2025-08-13
Richard Barasch
“Mr. Barasch’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-08-13
Jeremy Castle
“Mr. Castle’s resignation was not the result of any disagreement between Mr. Castle and the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-05-07
Maeve O'Meara
“Ms. O’Meara’s resignation is not the result of a disagreement with the Company or the Company’s Board of Directors or of any matter relating to the Company’s operations, financial statements, policies or practices.”
Resigned 2024-11-12
Robert Carter Appointed 2024-09-23
Robert Carter Appointed 2024-09-23
Mihir Shah
“His departure is not related to the operations, policies or practices of the Company or any issues regarding accounting policies or practices.”
Resigned 2024-09-23
Mihir Shah
“His departure is not related to the operations, policies or practices of the Company or any issues regarding accounting policies or practices.”
Resigned 2024-09-23
Jeremy N. Castle Appointed 2023-09-06
Ravi Sarin
“Mr. Sarin’s resignation was not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2023-09-01
Daniel Virnich Appointed 2023-06-12
Brad Hively
“Mr Hively’s resignation was not the result of any disagreement between Mr. Hively and the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2023-06-12
Matthew Miller, M.D. Terminated 2023-05-22
Diona Simoneit Resigned 2022-12-01
Gabriel Ling Appointed 2022-09-22
Mark Pacala Appointed 2022-09-22
Diona Simoneit Appointed 2022-04-04
Mihir Shah Appointed 2022-04-04
Matt Miller Appointed 2022-03-07
Matthew Miller Appointed 2022-03-07
Daniel Virnich Appointed 2022-03-07
Ravi Sarin Appointed 2021-11-18

Leadership

Key facts CIK 1799191 CUSIP 68236X100 13F (30d) 140 filings 127 filers Visit website Investor relations